



ALMA MATER STUDIORUM  
UNIVERSITÀ DI BOLOGNA

ARCHIVIO ISTITUZIONALE  
DELLA RICERCA

## Alma Mater Studiorum Università di Bologna Archivio istituzionale della ricerca

Depressive Symptoms and Amyloid Pathology

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

*Published Version:*

Wiels, W.A., Oomens, J.E., Engelborghs, S., Baeken, C., Von Arnim, C.A.F., Boada, M., et al. (2025).  
Depressive Symptoms and Amyloid Pathology. *JAMA PSYCHIATRY*, 82(3), 296-310  
[10.1001/jamapsychiatry.2024.4305].

*Availability:*

This version is available at: <https://hdl.handle.net/11585/1011778> since: 2025-03-29

*Published:*

DOI: <http://doi.org/10.1001/jamapsychiatry.2024.4305>

*Terms of use:*

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).  
When citing, please refer to the published version.

(Article begins on next page)

## Depressive symptoms and amyloid pathology: findings from the Amyloid Biomarker Study

Wietse A. Wiels<sup>1,2\*</sup>, Julie E. Oomens<sup>3\*</sup>, Sebastiaan Engelborghs<sup>4,5,6</sup>, Chris Baeken<sup>4,5,7,8</sup>, Nancy N. Maserejian<sup>9</sup>, Christine von Arnim<sup>10,11</sup>, Randall J. Bateman<sup>12</sup>, Mercè Boada<sup>13,14</sup>, Mira Didic<sup>15,16</sup>, Bruno Dubois<sup>17</sup>, Tormod Fladby<sup>18</sup>, Giovanni B. Frisoni<sup>19</sup>, Lutz Fröhlich<sup>20</sup>, Kiran Dip Gill<sup>21</sup>, Timo Grimmer<sup>22</sup>, Helmut Hildebrandt<sup>23</sup>, Jakub Hort<sup>24</sup>, Yoshiaki Itoh<sup>25</sup>, Takeshi Iwatsubo<sup>26</sup>, Aleksandra Klimkowicz-Mrowiec<sup>27</sup>, Susan M. Landau<sup>28</sup>, Dong Young Lee<sup>29</sup>, Alberto Lleó<sup>14,30</sup>, Pablo Martinez-Lage<sup>31</sup>, Alexandre de Mendonça<sup>32</sup>, Philipp T. Meyer<sup>33</sup>, Elisabeth N. Kapaki<sup>34</sup>, Piero Parchi<sup>35,36</sup>, Matteo Pardini<sup>37</sup>, Lucilla Parnetti<sup>38</sup>, Julius Popp<sup>39,40</sup>, Lorena Rami<sup>41</sup>, Eric M. Reiman<sup>42</sup>, Juha O. Rinne<sup>43</sup>, Karen M. Rodrigue<sup>44</sup>, Pascual Sánchez-Juan<sup>14,45</sup>, Isabel Santana<sup>46-48</sup>, Marie Sarazin<sup>49,50</sup>, Nikolaos Scarmeas<sup>51,52</sup>, Philip Scheltens<sup>53</sup>, Ingmar Skoog<sup>54</sup>, Peter J. Snyder<sup>55</sup>, Reisa A. Sperling<sup>56,57</sup>, Sylvia Villeneuve<sup>58-60</sup>, Gunhild Waldemar<sup>61,62</sup>, Anders Wallin<sup>63</sup>, Jens Wiltfang<sup>64,65</sup>, Henrik Zetterberg<sup>66-71</sup>, Daniel Alcolea<sup>14,30</sup>, Daniele Altomare<sup>72</sup>, Simone Baiardi<sup>73</sup>, Ines Baldeiras<sup>46-48</sup>, Kaj Blennow<sup>67</sup>, Michel Bottlaender<sup>74</sup>, Anouk den Braber<sup>53</sup>, Mark A. van Buchem<sup>75</sup>, Min Soo Byun<sup>29</sup>, Jiří Cerman<sup>24</sup>, Kewei Chen<sup>42</sup>, Elena Chipi<sup>38</sup>, Alisha Daniels<sup>76</sup>, Alexander Drzezga<sup>77</sup>, Marie Eckerström<sup>78</sup>, Laura L. Ekblad<sup>43</sup>, Stéphane Epelbaum<sup>17</sup>, Stefan Förster<sup>79,80</sup>, Juan Fortea<sup>14,30</sup>, Yvonne Freund-Levi<sup>81-83</sup>, Lars Frings<sup>33</sup>, Eric Guedj<sup>84</sup>, Ron Handels<sup>3</sup>, Lucrezia Hausner<sup>20</sup>, Sabine Hellwig<sup>85</sup>, Julio F. Jiménez-Bonilla<sup>86</sup>, Peter Johannsen<sup>87</sup>, Keith A. Johnson<sup>88</sup>, Ane Iriondo Juaristi<sup>31</sup>, Ramesh Kandimalla<sup>89-91</sup>, George Paraskevas<sup>34</sup>, Silke Kern<sup>66</sup>, Bjørn-Eivind S. Bordewick Kirsebom<sup>92,93</sup>, Johannes Kornhuber<sup>94</sup>, Julien Lagarde<sup>49</sup>, Nienke Legdeur<sup>53</sup>, Wolfgang Maier<sup>95</sup>, Marta Marquié<sup>13,14</sup>, Shinobu Minatani<sup>25</sup>, Silvia Daniela Morbelli<sup>96,97</sup>, Barbara Mroczko<sup>98,99</sup>, Eva Ntanasi<sup>100</sup>, Catarina Resende de Oliveira<sup>47</sup>, Pauline Olivieri<sup>49,50</sup>, Adela Orellana<sup>13,14</sup>, Oliver Peters<sup>86</sup>, Sudesh Prabhakar<sup>102</sup>, Inez H. Ramakers<sup>3</sup>, Eloy Rodríguez-Rodríguez<sup>103</sup>, Agustín Ruiz<sup>13,14</sup>, Eckart Rütger<sup>104</sup>, Per Selnes<sup>105</sup>, Dina Silva<sup>32</sup>, Hilka Soinen<sup>106,107</sup>, Luiza Spuru<sup>108,109</sup>, Akitoshi Takeda<sup>25</sup>, Marc Teichmann<sup>17</sup>, Betty M. Tijms<sup>53</sup>, Loisa I. Thompson<sup>110</sup>, Lisa Vermunt<sup>53</sup>, Jonathan Vogelgsangs<sup>111</sup>, Åsa K. Wallin<sup>112</sup>, Mary Yannakoulia<sup>100</sup>, Dahyun Yi<sup>113</sup>, Anna Zettergren<sup>66</sup>, for the Alzheimer's Disease Neuroimaging Initiative (ADNI)\*, A4 Study group, Dominantly Inherited Alzheimer Network (DIAN), Fundació ACE Healthy Brain Initiative (FACEHBI), Harvard Aging Brain Study (HABS), Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's disease (KBASE), Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) research group, Rik Ossenkoppele<sup>53,112</sup>, Frans R.J. Verhey<sup>3</sup>, Stephanie J.B. Vos<sup>3</sup>, Pieter Jelle Visser<sup>3,53,113</sup>, Willemijn J. Jansen<sup>3,42</sup>.

\*Contributed equally to this work

Target journal: JAMA Psychiatry | JAMA Network Open

Word count for manuscript: 2472/3000

## Affiliations

- 1 Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium
- 2 Department of Neurology, OLV Hospital, Aalst, Belgium
- 3 Maastricht University, Alzheimer Center Limburg, Department of Psychiatry & Neuropsychology, School for Mental Health and Neuroscience, Maastricht, the Netherlands
- 4 Vrije Universiteit Brussel (VUB), Center for Neurosciences, Neuroprotection & Neuromodulation (NEUR) Research Group, Brussels, Belgium
- 5 Universitair Ziekenhuis Brussel, Department of Neurology and Bru-BRAIN, Brussels, Belgium
- 6 University of Antwerp, Department of Biomedical Sciences, Antwerp, Belgium
- 7 Faculty of Medicine and Health Sciences, Department of Head and Skin, Ghent Experimental Psychiatry (GHEP) lab, Ghent University, Ghent, Belgium
- 8 Eindhoven University of Technology, Department of Electrical Engineering, Eindhoven, the Netherlands
- 9 Department of Epidemiology, Biogen, Cambridge MA, United States of America
- 10 Division of Geriatrics, University of Goettingen Medical School, Goettingen, Germany
- 11 Clinic for Neurogeriatrics and Neurological Rehabilitation, University and Rehabilitation Hospital Ulm, Ulm, Germany
- 12 Department of Neurology and the Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, United States of America
- 13 Ace Alzheimer Center Barcelona – Universitat Internacional de Catalunya, Barcelona, Spain
- 14 CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain
- 15 APHM, Timone, Service de Neurologie et Neuropsychologie, Hôpital Timone Adultes, Marseille, France
- 16 Aix Marseille Univ, INSERM, INS, Inst Neurosci Syst, Marseille, France
- 17 Department of Neurology, Institut de la Mémoire et de la Maladie d'Alzheimer, Centre de Référence Démences Rares, Hôpital de la Pitié-Salpêtrière, Assistance Publique– Hôpitaux de Paris (AP-HP), Paris, France
- 18 Department of Neurology, Akershus University Hospital, Lorenskog, Norway
- 19 Memory Clinic, University Hospitals and University of Geneva, Geneva, Switzerland
- 20 Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
- 21 Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh, India
- 22 Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technical University of Munich (TUM), School of Medicine and Health, Munich, Germany
- 23 Klinikum Bremen-Ost, University of Oldenburg, Institute of Psychology, Oldenburg, Germany
- 24 Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 25 Department of Neurology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
- 26 Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo, Japan
- 27 Department of Internal Medicine and Gerontology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland
- 28 Helen Wills Neuroscience Institute, University of California, Berkeley CA, United States of America
- 29 Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea
- 30 Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- 31 Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Spain
- 32 Faculty of Medicine, University of Lisboa, Lisboa, Portugal
- 33 Department of Nuclear Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
- 34 National and Kapodistrian University of Athens, School of Medicine, 1st Department of Neurology, Eginition Hospital, Athens, Greece
- 35 Istituto delle Scienze Neurologiche di Bologna, IRCCS, Bologna, Italy
- 36 Department of Biomedical and Neuromotor Sciences (DiBiNeM), University of Bologna, Bologna, Italy
- 37 DINOEMI, University of Genoa, Genoa, Italy
- 38 Centro Disturbi della Memoria, Laboratorio di Neurochimica Clinica, Clinica Neurologica, Università di Perugia, Perugia, Italy
- 39 Department of Geriatric Psychiatry, University Hospital of Psychiatry Zürich and University of Zürich, Zürich, Switzerland
- 40 Old Age Psychiatry, Department of Psychiatry, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland

41 Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic of Barcelona, IDIBAPS, Barcelona, Spain

42 Banner Alzheimer's Institute, Phoenix AZ, United States of America

43 Turku PET Centre, TYKS Turku University Hospital, Turku, Finland

44 Center for Vital Longevity, School of Behavioral and Brain Sciences, The University of Texas at Dallas, Richardson TX, United States of America

45 Alzheimer's Centre Reina Sofia-CIEN Foundation-ISCIII, Madrid, Spain

46 Faculty of Medicine, University of Coimbra, Coimbra, Portugal

47 Center for Neuroscience and Cell Biology - CIBB, University of Coimbra, Coimbra, Portugal

48 Neurology Department and Laboratory of Neurochemistry, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal

49 Department of Neurology of Memory and Language, Groupe Hospitalier Universitaire Paris Psychiatry and Neurosciences, Hôpital Sainte Anne, Paris, France

50 Université de Paris, Paris, Université Paris-Saclay, BioMaps, CEA, CNRS, INSERM, Orsay, France

51 1st Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece

52 Department of Neurology, Columbia University, New York City, New York 10027, United States of America

53 Department of Neurology, Alzheimer Centre Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands

54 Neuropsychiatric Epidemiology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden

55 Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, The University of Rhode Island, Kingston RI, United States of America

56 Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston MA, United States of America

57 Harvard Aging Brain Study, Department of Neurology, Harvard Medical School, Boston MA, United States of America

58 McConnell Brain Imaging Centre, Montreal Neurological Institute, Montreal, Quebec, Canada

59 Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, Quebec, Canada

60 Douglas Mental Health University Institute, Montreal, Quebec, Canada

61 Danish Dementia Research Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark

62 Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

63 Neuropsychiatric Epidemiology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden

64 Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany

65 Center of Neurology, Department of Neurodegeneration and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany

66 Neuropsychiatric Epidemiology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden

67 Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden

68 Department of Neurodegenerative Disease, University College London (UCL) Queen Square Institute of Neurology, London, United Kingdom

69 UK Dementia Research Institute, London, United Kingdom

70 Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China

71 Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, United States of America

72 Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

73 Department of Experimental Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Spain

74 Institut National de la Santé et de la Recherche Médicale (INSERM), BioMaps, Service Hospitalier Frederic Joliot, Orsay, France

75 Department of Radiology, University Medical Center Leiden, Leiden, the Netherlands

76 Department of Neurology, Washington University School of Medicine in St Louis, St Louis, MO, United States of America.

77 Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany

78 Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden

79 Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany

80 Department of Nuclear Medicine, Klinikum Bayreuth, Bayreuth, Germany

81 School of Medical Sciences, Örebro University, Örebro, Sweden

82 Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Karolinska Institutet Center for Alzheimer Research, Stockholm, Sweden

83 Department of Old Age Psychiatry, Psychology and Neuroscience, King's College, London, United Kingdom

84 Aix Marseille University, AP-HM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, Centre Européen de Recherche en Imagerie Médicale (CERIMED), Nuclear Medicine Department, Marseille, France

85 Department of Psychiatry and Psychotherapy Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany

86 Department of Nuclear Medicine, Marqués de Valdecilla University Hospital and IDIVAL, Santander, Spain

87 Memory Disorder Unit, Copenhagen University Hospital, Copenhagen, Denmark

88 Department of Radiology, Massachusetts General Hospital, Boston MA, United States of America

89 Department of Radiation Oncology, Emory University, Atlanta GA, United states of America

90 Applied Biology, Council of Scientific and Industrial Research (CSIR)-Indian Institute of Chemical Technology, Hyderabad, Telangana State, India

91 Department of Biochemistry, Kakatiya Medical College/Mahatma Gandhi Memorial Hospital, Warangal, Telangana State, India

92 Department of Neurology, University Hospital of North Norway, Tromsø, Norway

93 Department of Psychology, The Arctic University of Norway, Tromsø, Norway

94 Department of Psychiatry and Psychotherapy, University Hospital, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany

95 Department of Neurodegenerative Diseases and Geriatric Psychiatry, University of Bonn, Bonn, Germany

96 Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy

97 Ospedale Policlinico San Martino, IRCCS, Genoa, Italy

98 Department of Neurodegeneration Diagnostics, Medical University of Białystok, Białystok, Poland

99 Department of Biochemical Diagnostics, University Hospital of Białystok, Białystok, Poland

100 Department of Nutrition and Diatetics, Harokopio University, Kallithea, Athens, Greece

101 Charité Universitätsmedizin Berlin-CBF, Berlin, Germany

102 Department of Neurology, Nehru Hospital, Postgraduate Institute of Medical Education and Research, Chandigarh, India

103 Neurology Department, Hospital Universitario Marqués de Valdecilla and IDIVAL, University of Cambria, Santander, CIBERNED, Madrid, Santander, Spain

104 Department of Psychiatry and Psychotherapy, University Medical Center, Georg-August University, Göttingen, Germany

105 Department of Neurology, Akershus University Hospital, Lorenskog, Norway

106 Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland

107 Neurocenter, Department of Neurology, Kuopio University Hospital, Kuopio, Finland

108 Geriatrics, Gerontology and Old Age Psychiatry Clinical Department, Carol Davila University of Medicine and Pharmacy-Elias, Emergency Clinical Hospital, Bucharest, Romania

109 Memory Clinic and Longevity Medicine, Ana Aslan International Foundation, Bucharest, Romania

110 Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence RI, United States of America

111 Translational Neuroscience Laboratory, McLean Hospital, Harvard Medical School, Belmont, MA, United States of America

112 Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden

113 Institute of Human Behavioral Medicine, Medical Research Center Seoul National University, Seoul, Republic of Korea

114 Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Stockholm, Sweden

## **Key Points**

Question (1 sentence): What is the association between depressive symptoms and amyloid pathology in elderly individuals without dementia?

Findings (1-2 sentences): In this pooled analysis of 49 cohorts that included 12,769 participants, we found that the presence of depressive symptoms was not associated with amyloid pathology in participants with normal cognition but was associated with a lower frequency of amyloid pathology in participants with MCI.

Meaning (1 sentence): Mechanisms other than amyloid accumulation may commonly underly depressive symptomatology in later life.

## Abstract

**Importance:** Depressive symptoms are associated with cognitive decline in the elderly population. Uncertainty about underlying mechanisms hampers diagnostic and therapeutic efforts.

**Objective:** The aim of this study was to examine the association between depressive symptoms and amyloid pathology and its dependency on sex, education and *APOE* genotype in individuals without dementia.

**Design:** Cross-sectional analyses were performed using data from the Amyloid Biomarker Study data pooling initiative.

**Setting:** Data from 49 research studies, population-based studies and memory clinics was pooled and harmonized.

**Participants:** We included 9,746 individuals with normal cognition (NC) and 3,023 participants with MCI for whom data on amyloid biomarkers, presence of depressive symptoms, age, sex, and cognitive status was available.

**Exposures:** NA

**Main outcome(s) and measures(s):** A $\beta$ 1-42 levels in CSF or amyloid PET scans were used to determine presence or absence of amyloid pathology. Presence of depressive symptoms was determined on the basis of scores on validated depression rating scales, evidence of a current clinical diagnosis of depression or self-reported experience of depressive symptoms.

### **Results:**

The mean age of participants with NC was 69 years (58% female, 34% *APOE*  $\epsilon$ 4 carrier, 9.6% depressive symptoms, 27% amyloid pathology). The mean age of MCI participants was 70 years (49% female, 45% *APOE*  $\epsilon$ 4 carrier, 27% depressive symptoms, 56% amyloid pathology). In NC, the presence of depressive symptoms was not associated with amyloid pathology (OR = 1.1, 95%CI 0.90-1.40, p=0.29). In MCI, the presence of depressive symptoms was associated with a lower likelihood of amyloid pathology (OR = 0.73, 95%CI 0.61-0.89, p = 0.001). When considering subgroup effects, we found that, in NC, presence of depressive symptoms was associated with a higher frequency of amyloid pathology in *APOE*  $\epsilon$ 4 non-carriers (mean difference 5.0%, 95%CI 1.0-9.0%, p = 0.022), but not in carriers.

**Conclusion and relevance:** Depressive symptoms were not consistently associated with amyloid pathology in persons with NC and were associated with a lower likelihood amyloid of pathology in MCI participants. These findings indicate that mechanisms other than amyloid accumulation may commonly underly depressive symptoms in late life.

## Background

Depressive symptoms in the elderly are associated with future cognitive decline<sup>1,2</sup>. However, uncertainty about the exact causal direction and mechanisms hampers diagnostic and therapeutic efforts.

Much research has focused on examining the association between late-life depressive symptoms and amyloid pathology in relation to cognitive decline<sup>3-5</sup>. On the one hand, evidence exists for depressive symptoms as prodromal manifestations of neurodegeneration<sup>4,6</sup>. On the other hand, affective disorders, particularly more severe types such as major depressive disorder (MDD), may be an independent risk factor for cognitive decline<sup>5,7,8</sup>. In addition, cognitive decline and depressive symptoms share common risk factors<sup>9</sup>, raising the possibility of overlap without a direct causal relationship. Lastly, other findings suggest that late-life depression may be primarily mediated by non-amyloid pathology<sup>10</sup> or pathologies other than incipient AD<sup>11,12</sup>.

Heterogeneity in study design and populations, differences in severity of depressive complaints/diagnosis studied and biomarker modality utilized largely precludes the drawing of general conclusions<sup>13</sup>. Another source of heterogeneity in published research concerns the possible effects of the major genetic risk factor for sporadic Alzheimer's disease (AD) and the formation of brain amyloid plaques: the *APOE*  $\epsilon$ 4-allele.<sup>14,15</sup>

A better understanding of the association between depressive symptoms and amyloid pathology in elderly people without dementia is essential for further therapeutic research<sup>16</sup> and will aid diagnosis and prognosis in clinical settings. Therefore, the aim of the present study was to investigate the association between depressive symptoms and amyloid pathology and its dependence on age, sex, education and *APOE*  $\epsilon$ 4 carrier status in participants with normal cognition (NC) or mild cognitive impairment (MCI) included in the Amyloid Biomarker Study.

## Methods

### *Participants*

Participants for this cross-sectional study were selected from the Amyloid Biomarker Study, a data pooling initiative aiming to collate data from studies reporting information on positron-emission tomography (PET) or cerebrospinal fluid (CSF) amyloid markers<sup>17,18</sup>. For the current study, we selected all participants without dementia for whom data on amyloid biomarkers, age, and presence of depressive symptoms was available, leading to the inclusion of 12,769 participants from 49 centres (cohort characteristics described in **TABLE S1**). 9746 participants had NC as defined by normal scores on cognitive tests and/or absence of cognitive complaints. 3023 participants had MCI<sup>19,20,21</sup>. We did not investigate Subjective Cognitive Decline (SCD)<sup>22</sup> as a separate entity in this study.

### *Amyloid pathology*

Following procedures described previously, A $\beta$ 1-42 levels in CSF or amyloid PET scans were used to determine presence or absence of amyloid pathology<sup>23</sup>. Data-driven cut-offs from Gaussian Mixed Modelling (GMM) were applied to dichotomize data for 3775 participants (3579 CSF, 196 PET) and center-specific cut-offs were used to dichotomize data for 8994 participants (2345 CSF, 6649 PET)<sup>22</sup>.

### *Depressive symptoms and classification*

The presence of depressive symptoms was evaluated within 6 months of the amyloid assessment. Presence of depressive symptoms was operationalized in two ways, as defined below. **TABLE S2** shows an overview of the type and amount of data available per centre.

#### *1) Dichotomous presence or absence of depressive symptoms*

Participants were classified as having depressive symptoms if they (1) had a score on a validated depression rating scale indicating presence of mild, moderate or severe depressive symptoms (based on published clinical cut-offs, defined in supplemental **TABLE S3**; 11609 participants from 40 centres), (2) had a current clinical diagnosis of depression (228 participants from 7 centres) or (3) self-reported experiencing depressive symptoms (n=932 participants from 16 centres).

#### *2) Severity of depressive symptoms based on clinical cut-off values*

Based on their scores on validated depression rating scales, participants were classified as having no, mild, or moderate to severe depressive symptoms using published clinical cut-offs (defined in supplemental **TABLE S3**; rating scale data available for 11609 participants from 40 centres). Where multiple rating scale scores were available for a single participant, we chose to use data from the rating scale for which the most data was available across the Amyloid Biomarker Study population. Given the rarity of severe depression in the current sample, we chose to analyse moderate and severe depressive symptoms within a single category.

### *Statistical analysis*

Baseline differences in demographic and clinical characteristics of those with and without amyloid pathology were assessed using ANOVA or chi-square tests for continuous and categorical variables, respectively. We used generalized estimating equations to assess the association between depressive symptoms and amyloid pathology. We assumed a logit link function for binary outcomes with an exchangeable working correlation matrix and robust variance estimators to account for within-study correlation. Analyses were performed separately in the NC and MCI groups.

We first assessed the overall association between the presence of depressive symptoms and amyloid pathology. Next, we assessed the dependency of this association on age, sex, education (years of formal schooling), *APOE*  $\epsilon$ 4 carriership and number of *APOE*  $\epsilon$ 4 alleles. In secondary analyses, we assessed the association between depressive symptom severity and amyloid pathology. Finally, we examined the possible influence of amyloid measurement modality (i.e. CSF or PET) and the type of depression rating scale used (all rating scales for which the  $n > 100$ ) in post-hoc analyses. We also performed a sensitivity analysis for depressive symptom severity in which we used data-driven rather than clinical cut-offs. All analyses were corrected for age. Education was dichotomized at the mean (14 years of formal schooling).

The significance level was set at  $p=0.005$  (two-sided) and analyses were performed using IBM SPSS statistics v27. Figures were created using R (R Core Team, 2021. Foundation for Statistical Computing, Vienna, Austria).

## Results

### *Participant characteristics*

Descriptive characteristics for persons with NC (n=9746) and MCI (n=3023) are summarized in **TABLE 1**. Of participants with NC, 58% was female, 34% was *APOE*  $\epsilon$ 4 carrier, and 27% had amyloid pathology. NC participants had a mean age of 69 and had 15 years of education on average. NC participants with amyloid pathology were more likely to be older, male, *APOE*  $\epsilon$ 4 carrier and have depressive symptoms and were also more likely to have less years of education than NC participants without amyloid pathology. Of participants with MCI, 49% was female, 45% was *APOE*  $\epsilon$ 4 carrier and 56% had amyloid pathology. MCI participants had a mean age of 70 and had 12 years of education on average. MCI participants with amyloid pathology were more likely to be older and *APOE*  $\epsilon$ 4 carrier and were less likely to have depressive symptoms and moderate to severe depressive symptoms than MCI participants without amyloid pathology.

### *Association between depressive symptoms and amyloid pathology*

In persons with NC, the presence of depressive symptoms was not significantly associated with amyloid pathology (OR = 1.1, 95%CI 0.90-1.40, p=0.29). In MCI, the presence of depressive symptoms was associated with a lower likelihood of amyloid pathology (OR = 0.73, 95%CI 0.61-0.89, p = 0.001; **FIGURE 1A**).

In NC, there was a significant interaction of depressive symptoms with *APOE*  $\epsilon$ 4 carriership and number of *APOE*  $\epsilon$ 4 alleles. The presence of depressive symptoms was associated with a higher likelihood of amyloid pathology in *APOE*  $\epsilon$ 4 non-carriers (mean difference 5.0%, 95%CI 1.0-9.0%, p = 0.022) but not in *APOE*  $\epsilon$ 4 carriers (mean difference -1.0%, 95%CI -9.0-8.0%, p = 0.89; **FIGURE 2**). When considering number of *APOE*  $\epsilon$ 4 alleles, we likewise found that presence of depressive symptoms was associated with a higher likelihood of amyloid pathology in *APOE*  $\epsilon$ 4 non-carriers (mean difference 5.0%, 95%CI 1.0-9.0%, p = 0.019) but not in those with one (mean difference 1.0%, 95%CI -7.0-9.0%, p = 0.79) or two  $\epsilon$ 4 alleles (mean difference -12.0%, 95%CI -41.0%-18.0%, p = 0.44). In MCI, no interaction effects were found for *APOE*  $\epsilon$ 4 carrier status or number of *APOE*  $\epsilon$  alleles.

We did not find any interactions of age, sex or education with depressive symptoms for the NC or MCI groups (p = 0.84, p = 0.13 and p = 0.65 for NC; p = 0.88, p = 0.55 and p = 0.93 for MCI, respectively).

### *Association between depressive symptom severity and amyloid pathology*

In NC, severity of depressive symptoms was not significantly associated with amyloid pathology ( $p = 0.31$ ). In MCI, severity of depressive symptoms was associated with a higher likelihood of amyloid pathology (OR = 0.79, 95%CI 0.62-1.01,  $p = 0.064$  for mild vs. no symptoms; OR = 0.57, 95%CI 0.41-0.78,  $p < 0.001$  for moderate to severe vs. no symptoms; OR = 0.72, 95%CI 0.50-1.03,  $p = 0.072$  for moderate to severe vs. mild symptoms; **FIGURE 1B**). When evaluating the association between depressive symptom severity and amyloid pathology using data-driven rather than clinical cut-offs, we found a main effect of depression on amyloid pathology in NC but not in MCI. Results are detailed in the supplement.

### *Post hoc analyses*

In NC, there was an interaction between biomarker modality and presence of depressive symptoms. There was **an association between presence of depressive symptoms and amyloid pathology measured with CSF** ( $p$ -interaction 0.010, mean difference 5.0%, 95%CI 1.0-10.0%,  $p = 0.013$ ) while this association did not exist when amyloid was measured using PET (mean difference -3.0%, 95%CI -7.0-1.0%,  $p = 0.20$ ). In MCI, no significant interaction of biomarker modality with presence of depressive symptoms was noted.

In NC, there was **an interaction between rating scale used and presence of depressive symptoms** ( $p$  interaction 0.010). There was a significant difference in the prevalence of amyloid pathology between those with and without depressive symptoms if presence of depressive symptoms was measured using the Geriatric Depression Scale (GDS) 15 but not if measured by the Hospital Anxiety and Depression Scale (HADS), GDS30 or the Center for Epidemiologic Studies Depression Scale (CES-D). In MCI, there also was an interaction between rating scale used and presence of depressive symptoms ( $p$  interaction  $<0.001$ ) There was a significant difference in the prevalence of amyloid pathology between those with and without depressive symptoms if presence of depressive symptoms was measured using the Brief Symptom Inventory (BSI), GDS15, Montgomery Asberg Depression Rating Scale (MADRS) and CES-D but not if measured by the GDS30.

## Discussion

### *General findings on amyloid pathology and depressive symptoms*

The present study investigated the association of depressive symptoms with amyloid pathology in participants without dementia. In NC, presence and severity of depressive symptoms were not consistently associated with amyloid pathology. In MCI, presence and severity of depressive symptoms were associated with a lower likelihood of amyloid pathology. When considering subgroup effects, we found that, in NC, presence of depressive symptoms was associated with a higher frequency of amyloid pathology in *APOE*  $\epsilon$ 4 non-carriers but not in carriers. Findings suggest that mechanisms other than amyloid accumulation may underly presence of depressive symptomatology in late life.

In NC, no effect of depressive symptoms on amyloid pathology was identified. However, the lack of significant effects in individuals with NC must be interpreted in the light of a relatively low burden of depressive symptoms (9.6%) in this group. Nevertheless, this finding may suggest that amyloid pathology - i.e., prodromal or preclinical AD – does not play a major role in explaining (subsyndromal or mild) depressive symptoms in older adults with normal cognitive test scores. This finding may inform further research into preclinical neurodegeneration and/or subjective cognitive decline (SCD)<sup>24–26</sup>. Other studies have identified the absence of depressive symptoms as a predictor of amyloid pathology in SCD, a group included under NC in this study.<sup>25,26</sup> This may be due to the relatively high prevalence of depressive symptoms in SCD due to causes unrelated to degenerative disease.<sup>27</sup>

In participants with MCI, the presence of depressive symptoms was associated with a lower likelihood of amyloid positivity. This effect was more pronounced when considering severity of symptoms, demonstrating that individuals with MCI exhibiting mild and especially moderate to severe depressive symptoms are generally less likely to exhibit amyloid pathology compared to those without depressive symptoms. This observation may indicate that depressive symptoms and disorders are not generally caused by amyloid pathology, but may themselves play an independent causal role in cognitive decline, even suggesting some dose-response relationship<sup>3,28</sup>. Alternatively, this association may be mediated by non-amyloid (e.g., vascular) pathologies<sup>29–31</sup>. Indeed, a very large autopsy study of 741 individuals<sup>32</sup> recently supported this hypothesis, strengthening the so-called vascular hypothesis of geriatric depression<sup>33</sup>.

### *APOE, sex and education*

The presence of depressive symptoms in NC was associated with an increased likelihood of amyloid pathology in *APOE*  $\epsilon$ 4 non-carriers only. Several explanations of this finding are possible. For example, it may suggest an amyloidogenic mechanism triggered by depressive symptoms<sup>34,35</sup> that is not seen in those already predisposed to amyloid pathology by *APOE*  $\epsilon$ 4 alleles<sup>36</sup>, and may provide avenues for future research. None of the identified associations were dependent on sex or educational level. Compared with depressive disorders in younger adults, it remains unclear whether and how depressive disorders in aging women differ in frequency or quality from those in aging men.<sup>37-39</sup>

### *Diagnostic modality, rating scale effects and use of data-driven rather than clinical cut-offs*

In NC participants, depressive symptoms were associated with amyloid pathology only if assessed by CSF (n=5924) rather than PET (n=6845). This may be due to an intrinsic characteristic of CSF amyloid markers to diagnose amyloid abnormalities earlier than nuclear imaging techniques do<sup>40,41</sup>. Alternatively, it could reflect an independent pathophysiological signal<sup>42-44</sup> linking the soluble form of A $\beta$ 1-42 in CSF as opposed to the more static, fibrillary amyloid protein measured by PET, with low-grade depressive symptoms.<sup>45</sup>

In both NC and MCI, the association between presence of depressive symptoms and amyloid pathology was dependent on the rating scale used. One possible explanation may be that the depression scales included measure different aspects of the depressive symptom spectrum and that these may be differentially related to amyloid pathology<sup>46,47</sup>. Some of the rating scales used may also be more tailored to the specific population included in the study than others. For example, the GDS-15 may be more sensitive to symptoms of depression that are specifically related to cognitive impairment, or more prevalent in the aging population in general.<sup>48</sup> The differential result for the GDS15 and 30 in MCI is perhaps the most striking, but it has been noted before that both scales are not simply a longer or shorter version of the other<sup>55</sup>.

When we used data-driven rather than clinical cut-offs for depression severity, we found a significant association between severity of depressive symptoms and amyloid pathology in NC rather than MCI. This result is likely driven by the limited number of NC participants who have moderate to severe depressive symptoms when assessed using clinical cut-offs. However, this finding does imply that, in participants with NC, use of routine clinical cut-offs may not identify levels of depressive symptomatology that could be noteworthy in the light of risk for future pathology or decline.

## **Conclusion**


Overall, depressive symptoms are not consistently related to amyloid pathology in normal cognition, although possible differences by APOE $\epsilon$ 4 allele, biomarker modality and depression symptom measurement cut-offs used warrant further exploration. In participants with MCI, depressive symptoms were associated with a lower likelihood of amyloid pathology. These findings indicate that mechanisms other than amyloid accumulation may underly depressive symptoms in older adults without dementia.

## Tables and figures


Table 1: Participant characteristics								
	NC				MCI			
	Total, n = 9746	No Amyloid pathology, n = 7098	Amyloid pathology, n = 2648	P-value group comparison	Total, n = 3023	No Amyloid pathology, n = 1335	Amyloid pathology, n = 1688	P-value group comparison
Age, mean (SD)	68.6 (8.9)	67.8 (9.0)	70.6 (8.3)	P < 0.001	70.2 (8.7)	68.7 (9.1)	71.5 (8.2)	P < 0.001
Female, n(%)	5664 (58.2%)	4170 (58.7%)	1494 (56.6%)	P = 0.032	1481 (49.0%)	658 (49.3%)	823 (48.8%)	P = 0.77
Education years, mean (SD)	15.2 (3.8)	15.2 (3.8)	15.0 (3.9)	P = 0.002	11.8 (4.5)	11.7 (4.4)	12.0 (4.6)	0.10
<i>APOE</i> ε4 carrier, n(%)	3002 (34.0%)	1686 (26.1%)	1316 (56.0%)	P < 0.001	1046 (34.6%)	243 (24.3%)	803 (60.2%)	P < 0.001
Missing, n(%)	923 (9.5%)	627 (8.8%)	296 (11.2%)		689 (22.8%)	335 (25.1%)	354 (21.0%)	
Presence of depressive symptoms, n(%)	937 (9.6%)	649 (9.1%)	288 (10.9%)	P = 0.01	824 (27.3%)	428 (31.1%)	396 (23.5%)	P < 0.001
Symptom severity								
No depressive	8549 (91.1%)	6290 (91.5%)	2259 (90.2%)	P = 0.16	1696 (76.1%)	694 (71.3%)	1002 (79.8%)	P < 0.001

symptoms, n(%)								
Mild depressive symptoms, n(%)	711 (7.6%)	500 (7.3%)	211 (8.4%)		424 (19.0%)	211 (21.7%)	213 (17.0%)	
Moderate to severe symptoms, n(%)	120 (1.3%)	86 (1.3%)	34 (1.4%)		109 (4.9%)	69 (7.1%)	40 (3.2%)	
Missing, n(%)	366 (3.8%)	222 (3.1%)	144 (5.4%)		794 (26.3%)	361 (27.0%)	433 (25.7%)	

**Figure 1A & B: Prevalence of amyloid pathology by presence and severity of depressive symptoms**



**Figure 2: Prevalence of amyloid pathology by presence of depressive symptoms and APOE ε4 carrier status**



## Sources of funding

WW was an FWO (Fonds voor Wetenschappelijk Onderzoek Vlaanderen) Fundamental Research Fellow, Grant No. 11E8620N. This work was supported by the Geneeskundige Stichting Koningin Elisabeth / Fondation Médicale Reine Elisabeth. This study was funded by Biogen.

**Additional Contributions:** Members of the following groups, which contributed to this article, are listed in appendices 2-7 in the Supplement: Alzheimer's Disease Neuroimaging Initiative (ADNI), A4 Study group, Dominantly Inherited Alzheimer Network (DIAN), Fundació ACE Healthy Brain Initiative (FACEHBI), Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's disease (KBASE), and the Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) research group.

\*Data used in preparation of the present article were obtained from the ADNI database ([adni.loni.usc.edu](http://adni.loni.usc.edu)). As such, ADNI investigators provided and contributed to the design and implementation of the ADNI data but did not participate in the analysis or writing of this article. A complete listing of ADNI investigators can be found at [http://adni.loni.usc.edu/wp-content/uploads/how\\_to\\_apply/ADNI\\_Acknowledgement\\_List.pdf](http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf). The ADNI was launched in 2003 as a public-private partnership, led by principal investigator Michael W. Weiner, MD. The primary goal of ADNI is to test whether serial magnetic resonance imaging, PET, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment and early Alzheimer disease. Data collection and sharing for this project was funded by grant U01 AG024904 from the NIH and award W81XWH-12-2-0012 from the US Department of Defense. The ADNI is funded by the NIA; the National Institute of Biomedical Imaging and Bioengineering; and AbbVie, Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Araclon Biotech, BioClinica Inc, Biogen, Bristol-Myers Squibb Company, CereSpir Inc, Cogstate, Eisai Inc, Elan Pharmaceuticals Inc, Eli Lilly and Company, EuroImmun, F. Hoffmann-La Roche Ltd and its affiliated company Genentech Inc, Fujirebio, GE Healthcare, IXICO Ltd, Janssen Alzheimer Immunotherapy Research and Development LLC, Johnson & Johnson Pharmaceutical Research and Development LLC, Lumosity, Lundbeck, Merck & Co Inc, Meso Scale Diagnostics LLC, NeuroRx Research, Neurotrack Technologies, Novartis Pharmaceuticals Corporation, Pfizer Inc, Piramal Imaging, Servier, Takeda Pharmaceutical Company, and Transition Therapeutics. The Canadian Institutes of Health Research provides support to the ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the NIH ([www.fnih.org](http://www.fnih.org)). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute (ATRI) at the University of Southern California. The ADNI data are disseminated by the Laboratory for Neuroimaging at the University of Southern California.

The A4 and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) studies are led by Dr Sperling at Brigham and Women's Hospital, Harvard Medical School, and by Dr Paul Aisen at

the ATRI. The A4 and LEARN studies are coordinated by the ATRI, and the data are made available through the Laboratory for Neuroimaging. The participants screening for the A4 Study provided permission to share their deidentified data to advance the objective to find a successful treatment for Alzheimer disease. The A4 Study is a secondary prevention trial in preclinical Alzheimer disease that aims to slow cognitive decline associated with brain amyloid accumulation in clinically normal older individuals.

Data used in the preparation of this article were obtained from the Harvard Aging Brain Study (HABS; grant P01AG036694 from NIA; data release 2.0, obtained May 2021, via [habs.mgh.harvard.edu](https://habs.mgh.harvard.edu)). The HABS study was launched in 2010, is funded by the NIA, and is led by principal investigators Drs Sperling and Johnson at Massachusetts General Hospital, Harvard Medical School. A proportion of the data used in preparation of this article was obtained from the following: LEARN study, which was performed within the framework of the Center for Translational Molecular Medicine, a Dutch public-private partnership (project LEARN; grant 02 N-101 from Center for Translational Molecular Medicine); DIAN (grant UF01AG032438 from NIA), which was funded by the NIA, German Center for Neurodegenerative Diseases, Raul Carrea Institute for Neurological Research, and partially by the research and development grants for dementia from Japan Agency for Medical Research and Development and Korea Health Technology Research and Development Project through the Korea Health Industry Development Institute; and PREVENT-AD program (<https://douglas.research.mcgill.ca/stop-ad-centre>; data release 5.0, November 30, 2017), which provided and contributed to the design and implementation of PREVENT-AD data but did not participate in the analysis or writing of this article. A complete listing of PREVENT-AD research group investigators can be found at [http://preventad.loris.ca/acknowledgements/acknowledgements.php?date=\[2020=04-01\]](http://preventad.loris.ca/acknowledgements/acknowledgements.php?date=[2020=04-01]).

Data collection and sharing for this project was supported by The Dominantly Inherited Alzheimer Network (DIAN, U19AG032438) funded by the National Institute on Aging (NIA), the Alzheimer's Association (SG-20-690363-DIAN), the German Center for Neurodegenerative Diseases (DZNE), Raul Carrea Institute for Neurological Research (FLENI), Partial support by the Research and Development Grants for Dementia from Japan Agency for Medical Research and Development, AMED, and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), Spanish Institute of Health Carlos III (ISCIII), Canadian Institutes of Health Research (CIHR), Canadian Consortium of Neurodegeneration and Aging, Brain Canada Foundation, and Fonds de Recherche du Québec – Santé. This manuscript has been reviewed by DIAN Study investigators for scientific content and consistency of data interpretation with previous DIAN Study publications. We acknowledge the altruism of the participants and their families and contributions of the DIAN research and support staff at each of the participating sites for their contributions to this study.

The FACEHBI study was supported by funds from Fundació ACE Institut Català de Neurociències Aplicades, Grifols, Life Molecular Imaging, Araclon Biotech, Alkahest, Laboratorio de Análisis Echevarne and IrsiCaixa.

The KBASE cohort was funded by the Ministry of Health & Welfare, South Korea (HI18C0630 & HI19C0149), the Ministry of Science and ICT (NRF-2014M3C7A1046042), and the NIA, United States (U01AG072177). The overview of the study can be found at <http://kbase.kr/>

Part of the present study was supported by the European Medical Information Framework Alzheimer's Disease (EMIF- AD), which received support from the Innovative Medicines Initiative Joint Undertaking under EMIF-AD grant agreement 115372 that comprised financial contribution from the EU's Seventh Framework Program (FP7/2007-2013) and in kind contribution from EFPIA companies.

The Czech Brain Aging Study was supported by project No. LX22NPO5107 - Funded by the European Union – Next Generation EU..

The Sant Pau Memory Unit received funding from CIBERNED, ISCIII, which is jointly funded by FEDER, EU, Una manera de hacer Europa; Generalitat de Catalunya; Fundació La Marató TV3 Fundació Bancària Obra Social La Caixa; Fundación BBVA; Fundación Española para el Fomento de la Investigación de la Esclerosis Lateral Amiotrófica; Global Brain Health Institute; Fundació Catalana Síndrome de Down; and Fundació Víctor Grífols i Lucas.

The Phoenix Arizona APOE Cohort was funded by grant R01 AG031581 from the NIA.

The Imabio3 and Shata7-Imataustudies(Sarazin,Paris)were supported by grants PHRC-0054-N 2010 and PHRC-2013-0919 from the French Health Ministry, the Institut Roche de Recherche et Medecine Translationelle (Imabio3), Service Hospitalier FrédéricJoliot,FondationpourlaRecherchesur Alzheimer, Institut de Recherches Internationales Servier, and France-Alzheimer (Shata7-Imatau).

The Nijmegen cohort was supported by the BIONIC project (grant 733050822 from ZonMW-Memorabel as part of the Dutch National Deltaplan for Dementia [zonmw.nl/dementiaresearch]), the CAFÉ project (grant 5R01NS104147-02 from the NIH), and the Selfridges Group Foundation (grant NR170024).TheBIONICprojectisaconsortiumof Radboudumc, LUMC, ADX Neurosciences, and Rhode Island University.

A part data used for this research was originally obtained from the Japanese ADNI database. Japanese ADNI is led by Prof Iwatsubo and the database is available at the website of the NBDC Human Database (<https://biosciencedbc.jp/en/>) of the Japan Science and Technology Agency (JST).

## Disclosures

Dr Alcolea reported participating in advisory boards from Fujirebio-Europe and Roche Diagnostics; receiving speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka Farmacéutica SL, Zambon SAU, and Esteve Pharmaceuticals SA; and filing a patent application (WO2019175379 A1 Markers of Synaptopathy in Neurodegenerative Disease).

Dr Altomare received funding by the Fondation Recherche Alzheimer, and the Swiss National Science Foundation (project CRSK-3\_196354 / 1).

Dr von Arnim reported receiving honoraria from serving on the scientific advisory board of Biogen, Roche, and Dr Willmar Schwabe GmbH & Co KG; funding for travel and speaker honoraria from Lilly GmbH, Daiichi Sankyo, Biogen, Roche Diagnostics AG, and Dr Willmar Schwabe GmbH & Co KG; and research support from Roche Diagnostics AG.

Dr Boada reported funding from the Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER - Una manera de hacer Europa) grant PI17/01474; consulting for Araclon, Avid, Grifols, Lilly, Nutricia, Roche, Eisai and Servier, receiving fees from lectures and funds for research from Araclon, Biogen, Grifols, Nutricia, Roche and Servier and grants/research funding from Abbvie, Araclon, Biogen Research Limited, Bioiberica, Grifols, Lilly, S.A, Merck Sharp & Dohme, Kyowa Hakko Kirin, Laboratorios Servier, Nutricia SRL, Oryzon Genomics, Piramal Imaging Limited, Roche Pharma SA, and Schwabe Farma Iberica SLU.

Dr Hort has consulted Eisai, Biogen, Eli Lilly, Roche and Neurona lab and holds stock options in Alzheon company.

Dr Eckerström reported being employed as an independent reviewer at Medavante-Prophase.

Dr Engelborghs reported participating in consultancy or on advisory boards of Biogen, Danone, Eisai Inc, Icometrix, Pfizer, Novartis, and Roche, and receiving unrestricted research grants (paid to his institution) from ADx Neurosciences and Janssen Pharmaceuticals.

Dr Grimmer reported receiving consulting fees from AbbVie, Alector, Anavex, Biogen, Cogthera, Eli Lilly, Functional Neuromodulation, Grifols, Iqvia, Janssen, Noselab, Novo Nordisk, NuiCare, Orphanzyme, Roche Diagnostics, Roche Pharma, UCB, and Vivoryon; lecture fees from Biogen, Eisai, Grifols, Medical Tribune, Novo Nordisk, Roche Pharma, Schwabe, and Synlab; and has received grants to his institution from Biogen, Eisai, and Roche Diagnostics.

Dr Guedj reported having a scientific collaboration on amyloid positron emission tomography (PET) imaging with Life Molecular Imaging before 2018

Dr Jiménez-Bonilla reported funding from Investigative IDIVAL grant INNVAL-21-15.

Dr Kern reported honorarium for consulting for Geras Solutions and Biogen and Bioarctic.

Dr Marquié reported funding from the Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER - Una manera de hacer Europa) grant PI19/00335, consulting for F. Hoffmann-La Roche Ltd and participating in advisory boards from Araclon Biotech-Grifols.

Dr Maserejian is an employee and shareholder of Biogen, Inc.

Dr Mroczko has received consultation and/or lecture honoraria from Abbott, Wiener, Roche, Cormay, Biameditek, and TK Biotech companies.

Dr Nobili reported receiving fees for teaching courses from GE Healthcare and Biogen, for advisory board participation from Roche and Biogen, and for consultation from Bial.

Dr Ossenkoppelle has received research funding from European Research Council, ZonMw, NWO, National Institute of Health, Alzheimer Association, Alzheimer Nederland, Stichting Dioraphte, Cure Alzheimer's fund, Health Holland, ERA PerMed, Alzheimerfonden, Hjärnfonden and has reported receiving research support from Avid Radiopharmaceuticals, Janssen Research & Development, Roche, Quanterix and Optina Diagnostics, and has given lectures in symposia sponsored by GE Healthcare. He is an editorial board member of Alzheimer's Research & Therapy and the European Journal of Nuclear Medicine and Molecular Imaging.

Dr Popp reported receiving consultation and speaker honoraria from Nestle Institute of Health Sciences, Innovation Campus, EPFL, Ono Pharma, OM Pharma Suisse, and Fujirebio Europe.

Dr Ruiz reported receiving support from Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III (ISCIII); the EU/European Federation of Pharmaceutical Industries and Associations (EFPIA) Innovative Medicines Initiative Joint Undertaking; grants from the EXIT (Exosomes Isolation Tool with Nanofluidic Concentration Device) project, EU Euronanomed3 Program, and PREADAPT project; grant from the Joint Program for Neurodegenerative Diseases; and research funding from ISCIII Acción Estratégica en Salud, which was integrated in the Spanish National RCDCI Plan and financed by a grant from ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER; Una manera de hacer Europa) by Fundación Bancaria La Caixa and Grifols SA (GR@ACE project).

Dr Scheltens is a full time employee of EQT Life Sciences (formerly LSP) and Professor Emeritus at Amsterdam University Medical Centers. He has received consultancy fees (paid to the university) from Alzheon, Brainstorm Cell and Green Valley. Within his university affiliation he was global PI of the phase 1b study of AC Immune, Phase 2b study with FUJI-film/Toyama and phase 2 study of UCB. He is past chair of the EU steering committee of the phase 2b program of Vivoryon and

the phase 2b study of Novartis Cardiology and presently co-chair of the phase 3 study with NOVO-Nordisk.

Dr Snyder reported being a consultant to Alzheon Inc, AlzeCure Pharma, and AlzPATH Inc outside the submitted work.

Dr Soinen reported receiving personal consultation fees from AC Immune and Novo Nordisk outside the submitted work.

Dr Sperling reported receiving honorarium for consulting from AC Immune, Acumen, Alnylam, Cytos, Genentech, Janssen, JOMDD, Oligomerix, Neuraly, Neurocentria, Renew, Prothena, and Shionogi; reported receiving research funding from the National Institute on Aging (NIA), Alzheimer's Association, Eisai Inc, Eli Lilly and Company, and Janssen; and reported the following financial relationships for her spouse (Dr Keith Johnson): Cerveau, Janssen, AC Immune, and Novartis.

Dr A. Wallin reported receiving gratuity for lectures from Lundbeck.

Dr Zetterberg reported having served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Celectricon, Fujirebio, Lilly, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).

No other disclosures were reported.

**Consent statement**

All individual sites contributing to the Amyloid Biomarker Study have obtained local ethical approval and the Amyloid Biomarker Study was approved by the Medical Ethics Committee of the Maastricht University Medical Center which declared that the Medical Research Involving Human Subjects Act (WMO) does not apply to the study and waived the informed consent requirement because de-identified data were used.

**Data sharing statement: data management system**

## References

1. Saczynski JS, Beiser A, Seshadri S, Auerbach S, Wolf PA, Au R. Depressive symptoms and risk of dementia: The Framingham Heart Study. *Neurology*. 2010;75(1):35-41. doi:10.1212/WNL.0b013e3181e62138
2. Li G. Temporal Relationship Between Depression and Dementia. *Arch Gen Psychiatry*. 2011;68(9):970. doi:10.1001/archgenpsychiatry.2011.86
3. Saczynski JS, Beiser A, Seshadri S, Auerbach S, Wolf PA, Au R. Depressive symptoms and risk of dementia: The Framingham Heart Study. *Neurology*. 2010;75(1):35-41. doi:10.1212/WNL.0b013e3181e62138
4. Almeida OP, Hankey GJ, Yeap BB, Golledge J, Flicker L. Depression as a modifiable factor to decrease the risk of dementia. *Transl Psychiatry*. 2017;7(5):e1117-e1117. doi:10.1038/tp.2017.90
5. Larsen EN, Sloth MM, Osler M, Wium-Andersen IK, Jørgensen TSH. Depression in adulthood and risk of dementia later in life: A Danish register-based cohort study of 595,828 men. *J Affect Disord*. 2022;302:25-32. doi:10.1016/j.jad.2022.01.083
6. Sun X, Steffens DC, Au R, et al. Amyloid-Associated Depression. *Arch Gen Psychiatry*. 2008;65(5):542. doi:10.1001/archpsyc.65.5.542
7. Troubat R, Barone P, Leman S, et al. Neuroinflammation and depression: A review. *European Journal of Neuroscience*. 2021;53(1):151-171. doi:10.1111/ejn.14720
8. Burke SL, Maramaldi P, Cadet T, Kukull W. Associations between depression, sleep disturbance, and apolipoprotein E in the development of Alzheimer's disease: dementia. *Int Psychogeriatr*. 2016;28(9):1409-1424. doi:10.1017/S1041610216000405
9. Xu C, Cao Z, Huang X, Wang X. Associations of healthy lifestyle with depression and post-depression dementia: A prospective cohort study. *J Affect Disord*. 2023;327:87-92. doi:10.1016/j.jad.2023.01.111
10. Mackin RS, Insel PS, Landau S, et al. Late-Life Depression Is Associated With Reduced Cortical Amyloid Burden: Findings From the Alzheimer's Disease Neuroimaging Initiative Depression Project. *Biol Psychiatry*. 2021;89(8):757-765. doi:10.1016/j.biopsych.2020.06.017
11. Kuan-Yi Wu KJLCHCCYLYMWCSCTCYITH. Decreased Cerebral Amyloid- $\beta$  Depositions in Patients With a Lifetime History of Major Depression With Suspected Non-Alzheimer Pathophysiology. *Front Aging Neurosci*. 2022;14(2022).
12. Takamiya A, Vande Casteele T, Koole M, et al. Lower regional gray matter volume in the absence of higher cortical amyloid burden in late-life depression. *Sci Rep*. 2021;11(1):15981. doi:10.1038/s41598-021-95206-0
13. Wiels W, Baeken C, Engelborghs S. Depressive Symptoms in the Elderly—An Early Symptom of Dementia? A Systematic Review. *Front Pharmacol*. 2020;11. doi:10.3389/fphar.2020.00034
14. Delano-Wood L, Houston WS, Emond JA, et al. APOE genotype predicts depression in women with Alzheimer's disease: a retrospective study. *Int J Geriatr Psychiatry*. 2008;23(6):632-636. doi:10.1002/gps.1953
15. Tully PJ, Péres K, Berr C, Tzourio C. The APOE epsilon 4 polymorphism does not predict late onset depression: the Three-City Study. *Neurobiol Aging*. 2016;40:191.e9-191.e10. doi:10.1016/j.neurobiolaging.2015.12.018
16. van Dyck CH, O'Dell RS, Mecca AP. Amyloid-Associated Depression—or Not? *Biol Psychiatry*. 2021;89(8):737-738. doi:10.1016/j.biopsych.2021.02.008

17. Jansen WJ, Ossenkuppele R, Knol DL, et al. Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. *JAMA*. 2015;313(19):1924. doi:10.1001/jama.2015.4668
18. Jansen WJ, Janssen O, Tijms BM, et al. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. *JAMA Neurol*. 2022;79(3):228. doi:10.1001/jamaneurol.2021.5216
19. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. *J Intern Med*. 2004;256(3):240-246. doi:10.1111/j.1365-2796.2004.01380.x
20. Petersen RC. Mild cognitive impairment as a diagnostic entity. *J Intern Med*. 2004;256(3):183-194. doi:10.1111/j.1365-2796.2004.01388.x
21. Petersen RC. Mild cognitive impairment. *The Lancet*. 2006;367(9527):1979. doi:10.1016/S0140-6736(06)68881-8
22. Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. *Alzheimer's & Dementia*. 2014;10(6):844-852. doi:10.1016/j.jalz.2014.01.001
23. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Mol Med*. 2016;8(6):595-608. doi:10.15252/emmm.201606210
24. Ball HA, McWhirter L, Ballard C, et al. Functional cognitive disorder: dementia's blind spot. *Brain*. 2020;143(10):2895-2903. doi:10.1093/brain/awaa224
25. Ahn S, Mathiason MA, Yu F. Longitudinal Cognitive Profiles by Anxiety and Depressive Symptoms in American Older Adults With Subjective Cognitive Decline. *Journal of Nursing Scholarship*. 2021;53(6):698-708. doi:10.1111/jnu.12692
26. Hill NL, Bhargava S, Bratlee-Whitaker E, Turner JR, Brown MJ, Mogle J. Longitudinal Relationships Between Subjective Cognitive Decline and Objective Memory: Depressive Symptoms Mediate Between-Person Associations. *Journal of Alzheimer's Disease*. 2021;83(4):1623-1636. doi:10.3233/JAD-210230
27. Seong H, Park J. Symptom profiles and their influencing factors among people with subjective cognitive decline: a secondary analysis of cross-sectional data from the 2019 Korea Community Health Survey using latent class analysis. *BMJ Open*. 2023;13(8):e072236. doi:10.1136/bmjopen-2023-072236
28. Simões do Couto F, Lunet N, Ginó S, et al. Depression with melancholic features is associated with higher long-term risk for dementia. *J Affect Disord*. 2016;202:220-229. doi:10.1016/j.jad.2016.05.026
29. Alexopoulos GS. Mechanisms and treatment of late-life depression. *Transl Psychiatry*. 2019;9(1):188. doi:10.1038/s41398-019-0514-6
30. Wilson RS, Boyle PA, Capuano AW, et al. Late-life depression is not associated with dementia-related pathology. *Neuropsychology*. 2016;30(2):135-142. doi:10.1037/neu0000223
31. Golas AC, Salwierz P, Rajji TK, et al. Assessing the Role of Past Depression in Patients with Mild Cognitive Impairment, with and without Biomarkers for Alzheimer's Disease. *Journal of Alzheimer's Disease*. 2023;92(4):1219-1227. doi:10.3233/JAD-221097
32. Nunes PV, Suemoto CK, Rodriguez RD, et al. Neuropathology of depression in non-demented older adults: A large postmortem study of 741 individuals. *Neurobiol Aging*. 2022;117:107-116. doi:10.1016/j.neurobiolaging.2022.05.007

33. Jellinger KA. Pathomechanisms of Vascular Depression in Older Adults. *Int J Mol Sci*. 2021;23(1):308. doi:10.3390/ijms23010308
34. van Dyck CH, O'Dell RS, Mecca AP. Amyloid-Associated Depression—or Not? *Biol Psychiatry*. 2021;89(8):737-738. doi:10.1016/j.biopsych.2021.02.008
35. Lewis CK, Bernstein OM, Grill JD, Gillen DL, Sultzer DL. Anxiety and Depressive Symptoms and Cortical Amyloid- $\beta$  Burden in Cognitively Unimpaired Older Adults. *J Prev Alzheimers Dis*. Published online 2022. doi:10.14283/jpad.2022.13
36. Donovan NJ, Locascio JJ, Marshall GA, et al. Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults. *American Journal of Psychiatry*. 2018;175(6):530-537. doi:10.1176/appi.ajp.2017.17040442
37. Luppá M, Sikorski C, Luck T, et al. Age- and gender-specific prevalence of depression in latest-life – Systematic review and meta-analysis. *J Affect Disord*. 2012;136(3):212-221. doi:10.1016/j.jad.2010.11.033
38. Maier A, Riedel-Heller SG, Pabst A, Luppá M. Risk factors and protective factors of depression in older people 65+. A systematic review. *PLoS One*. 2021;16(5):e0251326. doi:10.1371/journal.pone.0251326
39. Cheung ESL, Mui AC. Gender Variation and Late-life Depression: Findings from a National Survey in the USA. *Ageing Int*. 2023;48(1):263-280. doi:10.1007/s12126-021-09471-5
40. Almdahl IS, Agartz I, Hugdahl K, Korsnes MS. Brain pathology and cognitive scores prior to onset of late-life depression. *Int J Geriatr Psychiatry*. 2022;37(3). doi:10.1002/gps.5686
41. Sala A, Nordberg A, Rodriguez-Vieitez E. Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid- $\beta$  positivity. *Mol Psychiatry*. 2021;26(10):5864-5874. doi:10.1038/s41380-020-00950-w
42. Gonzales MM, Insel PS, Nelson C, et al. Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment. *Int J Geriatr Psychiatry*. 2018;33(10):1305-1311. doi:10.1002/gps.4926
43. Nascimento KKF do, Silva KP, Malloy-Diniz LF, Butters MA, Diniz BS. Plasma and cerebrospinal fluid amyloid- $\beta$  levels in late-life depression: A systematic review and meta-analysis. *J Psychiatr Res*. 2015;69:35-41. doi:10.1016/j.jpsychires.2015.07.024
44. Loureiro JC, Stella F, Pais M V., et al. Cognitive impairment in remitted late-life depression is not associated with Alzheimer's disease-related CSF biomarkers. *J Affect Disord*. 2020;272:409-416. doi:10.1016/j.jad.2020.03.166
45. Palmqvist S, Zetterberg H, Mattsson N, et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. *Neurology*. 2015;85(14):1240-1249. doi:10.1212/WNL.0000000000001991
46. Seemüller F, Schennach R, Musil R, et al. A factor analytic comparison of three commonly used depression scales (HAMD, MADRS, BDI) in a large sample of depressed inpatients. *BMC Psychiatry*. 2023;23(1):548. doi:10.1186/s12888-023-05038-7
47. Krishnamoorthy Y, Rajaa S, Rehman T. Diagnostic accuracy of various forms of geriatric depression scale for screening of depression among older adults: Systematic review and meta-analysis. *Arch Gerontol Geriatr*. 2020;87:104002. doi:10.1016/j.archger.2019.104002

48. Mitchell AJ, Bird V, Rizzo M, Meader N. Diagnostic validity and added value of the geriatric depression scale for depression in primary care: A meta-analysis of GDS30 and GDS15. *J Affect Disord.* 2010;125(1-3):10-17. doi:10.1016/j.jad.2009.08.019

